Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RLY-5836

Small molecule · Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA) · developed by Relay Therapeutics

Phase 1 Most advanced trial (none active)
RLAY Developer
1 Registered trials

What is RLY-5836?

RLY-5836 is an orally bioavailable, pan-mutant selective inhibitor of the PI3K p110alpha catalytic subunit encoded by PIK3CA. It allosterically binds mutant forms of PIK3CA, preventing mutant-driven activation of the PI3K/Akt/mTOR pathway. It is being studied in PIK3CA-mutated solid tumors and breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA)
Mechanism
Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA)
Pathways
PI3K/Akt/mTOR pathway, apoptosis, growth inhibition
Therapy area
Oncology
Developer
Relay Therapeutics, Inc. (RLAY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05759949 Phase 1 PIK3CA Mutation Completed RLAY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Breast CancerBreast CancerHER2-negative Breast CancerHormone Receptor Positive TumorMetastatic Breast CancerPIK3CA MutationSolid Tumor, AdultUnresectable Solid Tumor

Other drugs acting on PIK3CA

More from Relay Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RLAY page.

Follow RLAY, the company behind RLY-5836

See RLAY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RLAY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.